GE HealthCare Technologies/$GEHC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GE HealthCare Technologies
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
- Ticker
- $GEHC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 54,000
- Headquarters
- Chicago, United States
- Website
- www.gehealthcare.com
GEHC Metrics
BasicAdvanced
$35B
16.15
$4.73
0.85
$0.14
0.18%
Price and volume
Market cap
$35B
Beta
0.85
52-week high
$89.77
52-week low
$58.75
Average daily volume
3.9M
Dividend rate
$0.14
Financial strength
Current ratio
1.304
Quick ratio
0.881
Long term debt to equity
0.866
Total debt to equity
0.877
Dividend payout ratio (TTM)
2.97%
Interest coverage (TTM)
7.55%
Profitability
EBITDA (TTM)
3,597
Gross margin (TTM)
39.28%
Net profit margin (TTM)
9.95%
Operating margin (TTM)
13.75%
Effective tax rate (TTM)
20.25%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
4.99%
Return on equity (TTM)
20.01%
Valuation
Price to earnings (TTM)
16.154
Price to revenue (TTM)
1.603
Price to book
2.98
Price to tangible book (TTM)
-6.47
Price to free cash flow (TTM)
18.357
Free cash flow yield (TTM)
5.45%
Free cash flow per share (TTM)
4.163
Dividend yield (TTM)
0.18%
Forward dividend yield
0.18%
Growth
Revenue change (TTM)
6.87%
Earnings per share change (TTM)
-2.07%
3-year revenue growth (CAGR)
3.91%
3-year earnings per share growth (CAGR)
11.96%
3-year dividend per share growth (CAGR)
17.23%
What the Analysts think about GEHC
Analyst ratings (Buy, Hold, Sell) for GE HealthCare Technologies stock.
Analyst projections of the future price of GE HealthCare Technologies stock.
Bulls say / Bears say
Q3 revenue grew 7.2% and adjusted EPS rose 25.1%. GE HealthCare beat its expectations and raised its 2026 organic revenue growth outlook to about 4% and adjusted EPS guidance to $4.95–$5.05. (Business Wire)
Orders exceeded sales in Q3, with a 1.03 book-to-bill ratio and a $23.7 billion backlog, supporting future revenue visibility. Q2 organic orders had grown 11.1%, showing strong customer demand earlier in the year. (Business Wire, GE HealthCare)
Flyrcado’s rollout and the planned SOFIE acquisition could grow radiopharmaceutical sales and strengthen US PET supply. Management said Flyrcado remains on track for a $500 million revenue run rate by the end of 2028. (Investing.com)
Patient Care Solutions revenue fell 13.3% in Q2 to $675 million, and management flagged a tougher Q4 comparison after the prior-year release of products that had been on hold. This makes a sustained recovery dependent on better execution. (Reuters, Investing.com)
Tariffs remain a major variable, while memory-chip and oil-related input costs continue to weigh on profits. Q3 margin gains also benefited from a favourable year-on-year tariff impact, so persistent cost pressure could make profitability harder to sustain. (Investing.com, Business Wire)
China’s reported Q3 growth of 7% was mostly driven by foreign exchange, so the underlying recovery may be weaker than the headline suggests. Local competition and volume-based procurement continue to add uncertainty and price pressure. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
GEHC Financial Performance
Revenues and expenses
GEHC Earnings Performance
Company profitability
Upcoming events
GEHC News
AllArticlesVideos
Funds containing GEHC
AllUSDEURGBP
Fund name | Fund size | $GEHC weighting |
|---|---|---|
VanEck Morningstar Wide Moat$MOAT | $396M | 2.44% |
VanEck Morningstar Wide Moat€GMVM | $376M | 2.44% |
VanEck Morningstar Wide Moat£MOGB | $376M | 2.44% |
iShares AI Adopters and Applications£AIAA | $188M | 0.64% |
iShares AI Adopters and Applications€AIAA | $188M | 0.64% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.